Pulmonary Sarcoidosis

Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study results published in CHEST.

Twelve weeks of online mindfulness-based cognitive therapy better alleviated sarcoidosis-related fatigue than standard care, according to study results published in The Lancet Respiratory Medicine.

Although rare organ involvement with sarcoidosis may be indicative of more severe disease, it often does not require treatment, according to data published in Respiratory Medicine.

A new review published in JAMA highlights the current diagnosis and treatment of pulmonary sarcoidosis.

Hospitalization rates in patients with sarcoidosis in Canada decreased over the past 20 years, researchers reported in the Annals of the American Thoracic Society.

A study recently published in The BMJ suggests that the number of total deaths worldwide due to chronic respiratory diseases has increased during the past 3 decades, although age-standardized mortality rates have generally declined.